Avita Medical (ASX:AVH) is a medical technology company that develops and commercialises regenerative medicine products for the treatment of chronic wounds. The company's flagship product is ReCell®, an autologous skin cell therapy that uses a patient's own skin cells to create a spray-on skin that is used to treat a variety of chronic wounds, including burns, diabetic ulcers, and pressure sores. Avita Medical is currently working on a number of projects, including the development of new ReCell® indications, the expansion of its global sales and marketing reach, and the development of new regenerative medicine products. Avita Medical's objectives are to become the leading provider of regenerative medicine products for the treatment of chronic wounds and to improve the lives of patients with chronic wounds.